Bicycle Therapeutics Announces Closing of Public Offering of American Depositary Shares and Non-Voting Ordinary Shares and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics plc (Nasdaq: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the closing on Monday, July 17, 2023 of its underwritten public offering of 6,117,648 American Depositary Shares (“ADSs”), each representing one ordinary share, which includes 1,411,764 ADSs sold upon the underwriters’ full exercise of their option to purchase additional ADSs, and 4,705,882 non-voting ordinary shares. The offering resulted in gross proceeds of approximately $230.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Bicycle.

Goldman Sachs & Co. LLC, Jefferies and Leerink Partners acted as joint book-running managers for the offering. The ADSs were offered pursuant to a “shelf” registration statement on Form S-3ASR that was filed by Bicycle with the Securities and Exchange Commission and automatically became effective upon filing. The offering was made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 1-866-471-2526, or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, or by email at [email protected]; or Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Contacts

David Borah, CFA

SVP, Capital Markets & Corporate Communications

[email protected]
617-203-8300